REPATHA (Amgen Inc)


Welcome to the PulseAid listing for the REPATHA drug offered from Amgen Inc. This PCSK9 Inhibitor [EPC],PCSK9 Inhibitors [MoA],Antibodies, Monoclonal [Chemical/Ingredient] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: Amgen Inc
NON-PROPRIETARY NAME: Evolocumab
SUBSTANCE NAME: EVOLOCUMAB
TYPE: HUMAN PRESCRIPTION DRUG
PHARMA CLASS: PCSK9 Inhibitor [EPC],PCSK9 Inhibitors [MoA],Antibodies, Monoclonal [Chemical/Ingredient]
ROUTE: SUBCUTANEOUS
DOSAGE FORM: INJECTION, SOLUTION
MARKETING CATEGORY NAME: BLA
START MARKETING DATE: 2015-08-31
END MARKETING DATE: 0000-00-00


REPATHA HUMAN PRESCRIPTION DRUG Details:

Item DescriptionREPATHA from Amgen Inc
LABELER NAME: Amgen Inc
DEA SCHEDULE:
ACTIVE STRENGTH: 140(mg/mL)
START MARKETING DATE: 2015-08-31
END MARKETING DATE: 0000-00-00
PRODUCT ID: 55513-750_108576bc-0544-443f-93ab-4e777b4cd590
PRODUCT NDC: 55513-750
APPLICATION NUMBER: BLA125522

Other EVOLOCUMAB Pharmaceutical Manufacturers / Labelers:

Manufacturer / LabelerProprietary Name
Amgen IncREPATHA